Infectivity of hepatic allografts with antibodies to hepatitis B virus.
about
Antibodies to hepatitis B surface antigen prevent viral reactivation in recipients of liver grafts from anti-HBC positive donorsEvidence of serious graft damage induced by de novo hepatitis B virus infection after liver transplantation.Prevention of de novo HBV infection by the presence of anti-HBs in transplanted patients receiving core antibody-positive livers.Improved detection of hepatitis B virus surface antigen by a new rapid automated assayHepatitis B in transplantation.Long-term efficacy of nucleoside monotherapy in preventing HBV infection in HBsAg-negative recipients of anti-HBc-positive donor livers.A concise update on the status of liver transplantation for hepatitis B virus: the challenges in 2002.Prophylaxis against de novo hepatitis B for liver transplantation utilizing hep B core (+) donors: does hepatitis B immunoglobulin provide a survival advantage?Use of hepatitis B core antibody-positive donors for liver transplantation.Current use of hepatitis B immune globulin for prevention of de novo hepatitis B in recipients receiving anti-HBc-positive livers.Extended criteria for organ acceptance. Strategies for achieving organ safety and for increasing organ pool.Utilization of hepatitis B core antibody-positive donor liver graftsIntravenous immunoglobulins in liver transplant patients: Perspectives of clinical immune modulation.Recent developments in the diagnosis and monitoring of HBV infection and role of the genetic variability of the S gene.Low prevalence of HBV DNA in the liver allograft from anti-HBc-positive donors: a single-center experience.Risk of de novo hepatitis in liver recipients from hepatitis-B core antibody-positive grafts - a systematic analysis.Long-term efficacy of hepatitis B vaccination as post-transplant prophylaxis in hepatitis B surface antigen (HBsAg) positive recipients and HBsAg negative recipients of anti-hepatitis B core positive grafts.De Novo Superinfection of Hepatitis B Virus in an Anti-HBs Positive Patient with Recurrent Hepatitis C Following Liver Transplantation.Transmission of hepatitis B infection from hepatitis B core antibody--positive liver allografts is prevented by lamivudine therapy.Transmission of hepatitis B infection from hepatitis B core antibody--positive livers: background and prevention.Safe use of livers from donors with positive hepatitis B core antibody.Clinical impact and efficacy of lamivudine therapy in de novo hepatitis B infection after liver transplantation.Hepatitis B virus markers in anti-HBc only positive individuals.Prevention of de novo hepatitis B infection in liver allograft recipients with previous hepatitis B infection or hepatitis B vaccination.History and prevention of de novo hepatitis B virus-related hepatitis in Japan and the world.Long-term lamivudine monotherapy prevents development of hepatitis B virus infection in hepatitis B surface-antigen negative liver transplant recipients from hepatitis B core-antibody-positive donors.Case report of lamivudine-resistant hepatitis B virus infection post liver transplantation from a hepatitis B core antibody donor.Use of an HBV-DNA hybridization assay in the evaluation of equivocal hepatitis B virus tests in solid organ donors.Evaluation of the antimicrobial activity and materials compatibility of orthophthalaldehyde as a high-level disinfectant.Reactivation of hepatitis B after liver transplantation: Current knowledge, molecular mechanisms and implications in management.
P2860
Q28344359-F027F35E-4DE4-42E1-BAA4-AD8E29EB6C58Q31921641-3F28AA6A-709E-480A-9EED-7AD12EBA850EQ33867301-E890ED39-6FAD-4977-A474-B1E3847DF34DQ33962073-3CC5B12D-77EB-47B8-8A22-2E24EB254BD2Q34294933-0773A702-F2E1-4168-86EE-970A94D3D45EQ34365421-050FD5F4-EFF5-4209-885D-5D3D8C167388Q34499694-82E8C309-0F52-4C15-82A2-843646EBCD4CQ34917705-94260432-0410-418D-A756-0BD1996F4615Q34936283-8152759D-49B4-4833-A85D-65BB59E26BAFQ34959703-782E79DC-FA7C-46B6-8501-15DE716244BCQ35180107-04C16CD6-A7BC-482F-AC39-D63AD4ADC8FBQ35658008-35D1F6B4-54B3-4235-B8AB-886BF572F736Q35715908-B32A3714-4DB0-440A-AD9E-AAB4CA65C5B3Q36050544-A39BBA4E-F84F-4A0C-9B53-6F3C0F1CA9E9Q36344884-A16B21E2-9764-4FC1-BB41-79BF39F13DC6Q37842669-015CD56A-EF58-455E-967A-9DBF19001946Q41390929-72997140-3CD1-4D9F-BEEF-D8685711BD2CQ42009223-10A6B74F-207B-4DCF-AE41-5BBA348829D1Q43666871-1A3B188F-2DAC-4F7C-A11E-F1A686EB5B84Q43666875-EE68154D-C190-49D8-98B4-22290C2B51B8Q44011089-4B606CDB-2E21-49A7-AF55-DB5974DCCEAAQ44165111-1899994A-A628-4F50-9FF7-464753CF217FQ44668301-3A6850FF-314B-4C38-B152-EC1546DD702EQ45047969-A55B5836-FFC1-4F47-A236-42E0078D010AQ45341288-7E95CF9E-C443-453F-9AFC-B0D012E13318Q45414817-905D128A-4E31-4B66-A303-4240498178A4Q45417753-C7F2766E-5776-490A-870D-F6A039827119Q45741070-D41B8DA0-9C09-4314-B8BA-A6C635FE985CQ46403776-37B11897-5FDE-493F-8762-3AB0561BDDC5Q52620441-A468F46E-0070-4516-B7D8-40D1AB854AEF
P2860
Infectivity of hepatic allografts with antibodies to hepatitis B virus.
description
1997 nî lūn-bûn
@nan
1997年の論文
@ja
1997年論文
@yue
1997年論文
@zh-hant
1997年論文
@zh-hk
1997年論文
@zh-mo
1997年論文
@zh-tw
1997年论文
@wuu
1997年论文
@zh
1997年论文
@zh-cn
name
Infectivity of hepatic allografts with antibodies to hepatitis B virus.
@en
type
label
Infectivity of hepatic allografts with antibodies to hepatitis B virus.
@en
prefLabel
Infectivity of hepatic allografts with antibodies to hepatitis B virus.
@en
P2093
P1433
P1476
Infectivity of hepatic allografts with antibodies to hepatitis B virus.
@en
P2093
Eghtesad B
Gayowski T
Iwatsuki S
Montalvo E
P304
P356
10.1097/00007890-199712150-00013
P577
1997-12-01T00:00:00Z